Journal Article

The Economic Burden of Drug Resistance

David H. Howard and R. Douglas Scott

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 41, issue Supplement_4, pages S283-S286
Published in print August 2005 | ISSN: 1058-4838
Published online August 2005 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/430792
The Economic Burden of Drug Resistance

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

In recent years, researchers have made substantial progress in the development of methods to measure the burden of resistance and the application of those methods to the limited data available. Our understanding of the costs incurred by patients infected with resistant strains in hospital settings is much better than it was 10, or even 5, years ago. Research on the impact of resistance in the community is more limited. When multiple treatment options are available and prescribed treatment is empirical, resistance will lead to higher expenditures on drugs but not necessarily to increased patient morbidity and mortality. Understanding to what degree prescribing patterns are driven by real versus perceived limitations of first-line drugs is important for assessing the ability of public health campaigns to change the behavior of patients and providers.

Journal Article.  2284 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.